Research programme: amyotrophic lateral sclerosis monoclonal antibodies - ALS Therapy Development Institute/Anelixis Therapeutics/Neurimmune

Drug Profile

Research programme: amyotrophic lateral sclerosis monoclonal antibodies - ALS Therapy Development Institute/Anelixis Therapeutics/Neurimmune

Alternative Names: NI 204; TDI 200

Latest Information Update: 09 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurimmune Therapeutics
  • Developer ALS Therapy Development Institute; Anelixis Therapeutics; Neurimmune Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors; Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 09 May 2018 Preclinical development in Amyotrophic lateral sclerosis is ongoing in USA (Parenteral) (Neurimmune pipeline, May 2018)
  • 28 Jan 2018 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral)
  • 06 Dec 2013 Preclinical trials in Amyotrophic lateral sclerosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top